We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Merck’s COVID-19 pill Lagevrio (molnupiravir) not only reduced the risk of hospitalization or death in patients with mild-to-moderate COVID-19 by 32.1 percent, it also reduced the chance of needing acute care visits for weeks after treatment ended, researchers reported in the Annals of Internal Medicine. Read More
Calling the results “a potential new standard-of-care” for pediatric brain tumors, Novartis said its chemotherapy combination of Tafinlar (dabrafenib) and Mekinist (trametinib) reduced the risk of disease progression or death in an ongoing study by 69 percent at 12 months, compared to standard chemotherapy. Read More
In a stunning mid-study analysis of 12 patients, GlaxoSmithKline’s anti-PD-1 antibody Jemperli (dostarlimab) completely eradicated locally advanced rectal tumors in every patient, sparing them life-altering surgery and causing minimal side effects. Read More
Breast cancer treatments by AstraZeneca (AZ)/Daiichi Sankyo and Gilead are grabbing headlines at the annual meeting of the American Society of Clinical Oncology this week. Read More
Johnson & Johnson’s (J&J) and AbbVie’s blockbuster cancer drug Imbruvica (ibrutinib) plus chemotherapy significantly slashed cancer spread in older patients suffering from mantle cell lymphoma (MCL) in a phase 3 study. Read More
Bristol Myers Squibb’s Orencia (abatacept) and Janssen’s Remicade (infliximab) reduced the risk of death among patients hospitalized with COVID-19 by around 40 percent, according to a study commissioned by the National Institutes of Health. Read More
Eight years after it shelved darapladib, GSK has sold the failed cardiovascular drug to startup SciNeuro Pharmaceuticals as a potential treatment for Alzheimer’s-associated cognitive decline. Read More